ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) will report first quarter 2026 financial results on May 6, 2026 after U.S. market close. Management will host a live conference call and audio webcast on May 6 at 4:30 p.m. ET.

Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the investor website.

News Market Reaction – ADMA

-2.75%

-2.75% Session close to close

In the Apr 29 session, ADMA declined 2.75%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for ADMA’s Q1 2026 reporting timeline, with results due on May 6...

Analysis

This announcement sets expectations for ADMA’s Q1 2026 reporting timeline, with results due on May 6, 2026 and a conference call at 4:30 p.m. ET. Historically, similar earnings date notices produced only modest share-price moves, indicating limited standalone impact. Investors may focus on how upcoming Q1 figures compare with ADMA’s record FY2025 performance and capital return plans once detailed results are disclosed.

Key Figures

Earnings release date: May 6, 2026 Conference call time: 4:30 p.m. ET

2 metrics

Earnings release date May 6, 2026 Q1 2026 financial results to be reported after market close

Conference call time 4:30 p.m. ET Q1 2026 results and company updates conference call

Previous Earnings date Reports

1 past event · Latest: Feb 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 18	Earnings date notice	Neutral	+0.3%	Announced Q4 and FY2025 earnings release date and conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date scheduling news led to a small, positive share-price reaction.

Recent Company History

Over recent months, ADMA has issued multiple updates, including record FY2025 financial results on Feb 25, 2026 and a substantial 2026 share repurchase initiative. An earlier earnings date notice on Feb 18, 2026 produced only a modest 0.25% move, suggesting such scheduling announcements have historically been low-volatility events. The current notice setting the first quarter 2026 report and call date fits this pattern of routine investor communications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM^® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:

Argot Partners | 212-600-1902 | ADMA@argotpartners.com

MEDIA CONTACT:

Longacre Square Partners | ADMABiologics@longacresquare.com

FAQ

When will ADMA (Nasdaq: ADMA) report Q1 2026 financial results?

ADMA will report Q1 2026 results on May 6, 2026 after U.S. markets close. According to the company, a live conference call and audio webcast are scheduled for 4:30 p.m. ET the same day to discuss results and updates.

How can I join the ADMA May 6, 2026 conference call and webcast?

Register in advance to receive dial-in numbers and a unique PIN for the conference call. According to the company, webcast listeners can join without asking questions and should register via the investor site links provided.

Will ADMA provide a replay of the May 6, 2026 earnings call for ADMA shareholders?

Yes. An archived replay will be available under Events & Webcasts on ADMA's investor website. According to the company, the replay will be posted after the live event for on-demand access.

What topics will ADMA management cover on the May 6, 2026 call for ADMA (Nasdaq: ADMA)?

Management will discuss first quarter 2026 financial results and other company updates. According to the company, the call is intended to review reported results and provide context on recent business developments.

Is there a recommended time to join ADMA's May 6, 2026 conference call?

Participants are recommended to join about 10 minutes before the 4:30 p.m. ET start time. According to the company, early login helps ensure seamless access using the provided dial-in numbers and PIN.